Mirum Pharmaceuticals, Inc. $MIRM Stock Holdings Trimmed by Eventide Asset Management LLC

Eventide Asset Management LLC trimmed its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 17.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 2,093,582 shares of the company’s stock after selling 428,981 shares during the period. Mirum Pharmaceuticals comprises 2.6% of Eventide Asset Management LLC’s investment portfolio, making the stock its 3rd largest position. Eventide Asset Management LLC’s holdings in Mirum Pharmaceuticals were worth $165,370,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. purchased a new stake in Mirum Pharmaceuticals in the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in Mirum Pharmaceuticals in the fourth quarter worth $32,000. CIBC Private Wealth Group LLC purchased a new stake in Mirum Pharmaceuticals in the fourth quarter worth $32,000. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the third quarter worth $33,000. Finally, Quarry LP purchased a new stake in Mirum Pharmaceuticals in the third quarter worth $41,000.

Analyst Upgrades and Downgrades

MIRM has been the topic of several recent research reports. Citizens Jmp reaffirmed a “market outperform” rating and issued a $132.00 price target on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 21st. Leerink Partners reduced their price target on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. HC Wainwright set a $185.00 price target on Mirum Pharmaceuticals in a research note on Thursday, May 7th. Evercore reaffirmed an “outperform” rating and issued a $138.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Finally, Stifel Nicolaus set a $136.00 price target on Mirum Pharmaceuticals in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.36.

Mirum Pharmaceuticals Trading Down 0.2%

Shares of NASDAQ:MIRM opened at $99.35 on Friday. The company has a market cap of $6.06 billion, a P/E ratio of -7.30 and a beta of 0.50. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. Mirum Pharmaceuticals, Inc. has a 1 year low of $47.89 and a 1 year high of $114.99. The stock’s fifty day moving average price is $97.89 and its 200-day moving average price is $91.13.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The business had revenue of $159.88 million for the quarter, compared to the consensus estimate of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.30) earnings per share. Sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Insider Activity

In other news, COO Peter Radovich sold 16,515 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $1,519,049.70. Following the transaction, the chief operating officer directly owned 40,272 shares of the company’s stock, valued at $3,704,218.56. This represents a 29.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jolanda Howe sold 4,732 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $435,249.36. Following the transaction, the senior vice president directly owned 8,429 shares in the company, valued at approximately $775,299.42. The trade was a 35.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 111,806 shares of company stock valued at $10,408,916. Corporate insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.